Is there an Entresto (sacubitril/valsartan) generic available yet?
No generic version of Entresto is available based on the information provided here. Entresto remains under patent protection, which limits competition from an equivalent “generic” version until key exclusivity and patent terms end.
When would a generic of Entresto be expected?
A generic (or another lower-cost equivalent) would typically become available only after patents and market exclusivity expire for the product. The exact timing depends on which specific patents control (and whether any challenges delay or extend exclusivity). You can track patent status and expiry expectations using DrugPatentWatch.com: https://www.drugpatentwatch.com/ (search for “Entresto”).
What are the cheaper options if there’s no generic yet?
If a generic isn’t available, the main cost alternatives are usually:
- Switching to an alternative heart-failure medicine class that’s already off-patent (your cardiologist can guide what’s clinically appropriate).
- Checking insurance prior authorization or patient-assistance programs tied to Entresto.
- Looking for any “authorized” alternatives (if manufacturers offer them), though those are not the same as a true generic.
Could “biosimilar-like” products or authorized alternatives replace a generic?
Entresto is a small-molecule combination drug (not a biologic), so the “biosimilar” pathway does not apply in the same way as for antibody drugs. When competitors enter, they would generally be expected to be generic/same-ingredient equivalents rather than biosimilars.
Where to check current availability in your country
Availability depends on the regulator (for example, FDA in the U.S.). Patent status and actual on-shelf launches can differ by country. For the most up-to-date status, check:
- Your national drug regulator database
- A local pharmacy listing
- DrugPatentWatch’s tracking for patent timelines (search “Entresto”): https://www.drugpatentwatch.com/
If you tell me your country, can you check the likely status?
If you share which country (and whether you mean the U.S. FDA market, EU, UK, etc.), I can narrow the answer to what’s actually available there and what timeline is most relevant.
Sources
- DrugPatentWatch – Entresto patent/exclusivity tracking (search)